MYC and neoplasm: In breast cancer, several lines of evidence have implicated overexpression of EZH2 and repression of tumor suppressors such as KRT5, KRT6, CDH3, RAD51 paralogs, CDKN1C, FOXC1, Wnt/β-catenin signaling (c-Myc, Cyclin D1, Axin2), RKIP and KLF2 [21].